RECOMBINANT HUMAN GROWTH-HORMONE TREATMENT OF CHILDREN WITH CHRONIC-RENAL-FAILURE - LONG-TERM (1-YEAR TO 3-YEAR) OUTCOME

被引：53

作者：

FINE, RN

PYKEGRIMM, K

NELSON, PA

BOECHAT, MI

LIPPE, BM

YADIN, O

KAMIL, E

机构：

[1] Department of Pediatrics, University of California at Los Angeles, Center for Health Sciences, Los Angeles, California

[2] Division of Pediatric Nephrology, University of California at Los Angeles, Center for Health Sciences, Los Angeles, California

[3] Department of Radiology, University of California at Los Angeles, Center for Health Sciences, Los Angeles, California

[4] Division of Pediatric Endocrinology, University of California at Los Angeles, Center for Health Sciences, Los Angeles, California

来源：

PEDIATRIC NEPHROLOGY | 1991年 / 5卷 / 04期

关键词：

CHRONIC RENAL FAILURE; GROWTH RETARDATION; HUMAN GROWTH HORMONE;

D O I：

10.1007/BF01453685

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Treatment of nine boys, aged 2.8-16.3 years, with growth retardation consequent to chronic renal failure (CRF), with recombinant human growth hormone (rhGH) for 12-36 months demonstrated a significant improvement in growth velocity at each 12-month interval compared with that achieved the year prior to treatment. Despite the acceleration in growth velocity the bone age did not increase more than the increase in chronological age during the period of treatment. The mean calculated creatinine clearance did not decrease significantly during the 36 months of treatment; however, two patients required institution of dialysis at 18 and 30 months following the initiation of rhGH treatment. There was no exacerbation of the glucose intolerance of uremia following rhGH treatment. Currently, six of seven patients who have been treated for more than 24 months have achieved sufficient acceleration of growth velocity to attain a standard deviation score that was more positive than -2.00, and are above the 5th per centile for chronological age on the growth curve. These data indicate that rhGH treatment of growth-retarded children with CRF results in accelerated growth velocity during the 2nd and 3rd years of treatment, and demonstrate the potential for such children to achieve normal stature for chronological age despite the continued presence of renal failure.

引用

页码：477 / 481

页数：5

共 18 条

[1]

Mehls O., Ritz E., Skeletal growth in experimental uremia, Kidney Int, pp. S53-S60, (1983)

[2]

Mehls O., Ritz E., Hunziker E.E., Eggli P., Heinrich U., Zapf J., Improvement of growth and food utilization by human recombinant growth hormone in uremia, Kidney Int, 33, pp. 45-52, (1988)

[3]

Powell D.R., Rosenfeld R.G., Hintz R.L., Effects of growth hormone therapy and malnutrition on the growth of rats with renal failure, Pediatr Nephrol, 2, pp. 425-430, (1988)

[4]

Nakano M., Kainer G., Foreman J.W., Ko D., Chan J.C.M., The effects of exogenous rat growth hormone therapy on growth of uremic rats fed an 8% protein diet, Pediatr Res, 26, pp. 204-207, (1989)

[5]

Lippe B.M., Fine R.N., Koch V.H., Sherman B.M., Accelerated growth following recombinant human growth hormone (rhGH) in children with chronic renal failure, Acta Paediatr Scand, 343, pp. S127-S131, (1988)

[6]

Koch V.H., Lippe B.M., Nelson P.A., boechat M.I., Sherman B.M., Fine R.N., Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure, J Pediatr, 115, pp. 365-371, (1989)

[7]

Fine R.N., Koch V.H., Nelson P.A., Boechat M.I., Fine S.E., Sherman B.M., Lippe B.H., Recombinant human growth hormone (rhGH) treatment of children with renal insufficiency, Adv Nephrol, 19, pp. 187-208, (1990)

[8]

Schwartz G.J., Haycock M.B., Edelmann C.M., Spitzer A., A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine, Pediatrics, 58, pp. 259-263, (1976)

[9]

Fass B., Lippe B.M., Kaplan S.A., Relative usefulness of three growth hormone stimulating tests, Am J Dis Child, 133, pp. 931-933, (1979)

[10]

Powell D.R., Rosenfeld R.G., Sperry J.B., Baker B.K., Hintz R.L., Serum concentrations of insulin-like growth factors (IGF-1), IGF-2 and unsaturated somatomedin carrier proteins in children with chronic renal failure, Am J Kidney Dis, 4, pp. 287-292, (1987)

← 1 2 →